Skip to content

Kazia Therapeutics up on U.S. accelerated review tag for lead drug

August 20, 2020

Nano cap Kazia Therapeutics Limited (NASDAQ:KZIA) jumps 21% premarket on robust volume in reaction to Fast Track status in the U.S. for lead drug paxalisib for a type of brain cancer called glioblastoma.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

Shares rallied in April when it reported positive preliminary data from a mid-stage study. Additional data should be available this year with final results expected in H1 2021.

Paxalisib, in-licensed from Roche in 2016, modulates an intracellular pathway called PI3K that plays a key role in cell growth, proliferation, survival and angiogenesis (growth of blood vessels).

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: